You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lubinga SJ, Payer T, Lee L, et al
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0589